Flagship Harbor Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Flagship Harbor Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$4.37K	–	785
2025 Q4	$4.37K	Buy	+11	New	+$4.87K	﹤0.01%	1685
2020 Q4	–	Sell	-559	Closed	-$81K	–	607
2020 Q3	$81K	Hold	559	–	–	0.01%	712
2020 Q2	$82K	Buy	559 +15	+3%	+$2.02K	0.01%	708
2020 Q1	$59K	Hold	544	–	–	0.01%	705
2019 Q4	$63K	Buy	544 +33	+6%	+$3.29K	0.01%	747
2019 Q3	$41K	Hold	511	–	–	0.01%	832
2019 Q2	$37K	Hold	511	–	–	0.01%	852
2019 Q1	$47K	Buy	+511	New	+$42.7K	0.01%	768

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Flagship Harbor Advisors's ALNY Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 11 shares — an estimated $4.37K sold.

Flagship Harbor Advisors first reported a position in ALNY in Q1 2019 and held it in 8 quarters. The position peaked at $82K in Q2 2020. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Flagship Harbor Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 11 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $4.37K.
Flagship Harbor Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2019 and held it in 8 quarters.
Flagship Harbor Advisors's Alnylam Pharmaceuticals position peaked at $82K in Q2 2020.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.